CN103002904B - 抗血管生成药剂及使用这种药剂的方法 - Google Patents

抗血管生成药剂及使用这种药剂的方法 Download PDF

Info

Publication number
CN103002904B
CN103002904B CN201180034591.9A CN201180034591A CN103002904B CN 103002904 B CN103002904 B CN 103002904B CN 201180034591 A CN201180034591 A CN 201180034591A CN 103002904 B CN103002904 B CN 103002904B
Authority
CN
China
Prior art keywords
polypeptide
sequence
mice
mankind
structure domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180034591.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103002904A (zh
Inventor
刘志仁
詹妮·J·杨
鲁荫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia State University Research Foundation Inc
Original Assignee
Georgia State University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia State University Research Foundation Inc filed Critical Georgia State University Research Foundation Inc
Publication of CN103002904A publication Critical patent/CN103002904A/zh
Application granted granted Critical
Publication of CN103002904B publication Critical patent/CN103002904B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201180034591.9A 2010-07-13 2011-07-13 抗血管生成药剂及使用这种药剂的方法 Active CN103002904B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36393310P 2010-07-13 2010-07-13
US61/363,933 2010-07-13
PCT/US2011/043907 WO2012009471A1 (en) 2010-07-13 2011-07-13 Anti-angiogenic agent and method of using such agent

Publications (2)

Publication Number Publication Date
CN103002904A CN103002904A (zh) 2013-03-27
CN103002904B true CN103002904B (zh) 2017-01-18

Family

ID=44629339

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180034591.9A Active CN103002904B (zh) 2010-07-13 2011-07-13 抗血管生成药剂及使用这种药剂的方法

Country Status (12)

Country Link
US (2) US9175063B2 (enExample)
EP (2) EP2593127B1 (enExample)
JP (2) JP6353654B2 (enExample)
CN (1) CN103002904B (enExample)
AU (5) AU2011279155B2 (enExample)
CA (1) CA2804753C (enExample)
DK (1) DK2593127T3 (enExample)
ES (2) ES2923430T3 (enExample)
HU (1) HUE040205T2 (enExample)
PL (1) PL2593127T3 (enExample)
PT (2) PT2593127T (enExample)
WO (1) WO2012009471A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040205T2 (hu) * 2010-07-13 2019-02-28 Georgia State Univ Research Foundation Anti-angiogén szer, és egy ilyen szer alkalmazási módja
CN107709354B (zh) * 2015-03-06 2022-01-04 乔治亚州立大学研究基金会 整合素靶向蛋白和其使用方法
CN110498851B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物及应用
CN108148117A (zh) * 2017-12-26 2018-06-12 张艳雪 一种抗菌肽的蛋白质结构特性及其研究方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
CN1953766A (zh) * 2004-02-06 2007-04-25 安斯泰来美国有限公司 治疗皮肤病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP1539234A4 (en) * 2002-09-05 2006-02-15 Medimmune Inc METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
US9339559B2 (en) * 2005-09-09 2016-05-17 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
EP3498307A1 (en) * 2008-04-02 2019-06-19 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
JP5792066B2 (ja) * 2008-09-08 2015-10-07 ホフマン／バーレット， リミテッド ライアビリティ カンパニー ポルフィラジン並びに光学的及びデュアル光学的／ｍｒコントラスト並びに治療薬
HUE040205T2 (hu) * 2010-07-13 2019-02-28 Georgia State Univ Research Foundation Anti-angiogén szer, és egy ilyen szer alkalmazási módja

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
CN1953766A (zh) * 2004-02-06 2007-04-25 安斯泰来美国有限公司 治疗皮肤病的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N-glycosylation is required for human CD2 immunoadhesion function;RECNY;《Journal of biological chemistry》;19920101;第267卷(第31期);第22428页 *

Also Published As

Publication number Publication date
AU2017201133A1 (en) 2017-03-09
HUE040205T2 (hu) 2019-02-28
CA2804753A1 (en) 2012-01-19
US20130281357A1 (en) 2013-10-24
AU2023202513A1 (en) 2023-05-11
US11578114B2 (en) 2023-02-14
CN103002904A (zh) 2013-03-27
AU2021201207A1 (en) 2021-03-11
JP2013534538A (ja) 2013-09-05
EP2593127B1 (en) 2018-05-30
US20160090408A1 (en) 2016-03-31
AU2011279155A1 (en) 2013-01-24
WO2012009471A1 (en) 2012-01-19
PT2593127T (pt) 2018-07-06
JP6353654B2 (ja) 2018-07-04
CA2804753C (en) 2021-05-25
AU2011279155B2 (en) 2017-03-09
JP2016175913A (ja) 2016-10-06
EP3381462B1 (en) 2022-06-08
EP2593127A1 (en) 2013-05-22
US9175063B2 (en) 2015-11-03
AU2019202174A1 (en) 2019-04-18
DK2593127T3 (en) 2018-07-02
PT3381462T (pt) 2022-07-22
PL2593127T3 (pl) 2018-11-30
ES2923430T3 (es) 2022-09-27
ES2674409T3 (es) 2018-06-29
EP3381462A1 (en) 2018-10-03
AU2019202174B2 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
AU2023202513A1 (en) Anti-angiogenic agent and method of using such agent
JP2024156682A (ja) 癌幹細胞を標的とした癌ワクチン
US20210008173A1 (en) Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
JP2025078632A (ja) インテグリン標的タンパク質およびその使用方法
US20240390465A1 (en) Endostatin Peptides for the Treatment of Tumors, Fibrosis and Acute Lung Injury
US12410230B2 (en) Anti-angiogenic agent and methods of using such agent
WO2024173546A2 (en) Anti-angiogenic agent and methods of using such agent
CN121240871A (zh) 抗血管生成剂和使用这种剂的方法
US20230241167A1 (en) Use of Caveolin-1 Scaffolding Domain Peptides for Treating Disease and Disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant